A new approach to prostate cancer.

Abstract

Growth of androgen-dependent human prostatic adenocarcinoma implanted in the nude mouse (Honda tumour), is inhibited by 6-methyleneprogesterone. This steroid is a potent inhibitor of both rat and human prostatic 5 alpha-reductase in-vitro. In-vivo, at the studied dose level, it reduces metabolic conversion of testosterone to dihydrotestosterone with minimal effects upon circulating LH and testosterone. These data support the hypothesis that dihydrotestosterone and not testosterone is the main trophic androgen of the human prostatic neoplasm.

• Authors: Y Z Ito, Y Nakazato, V Petrow
• Journal: The Journal of pharmacy and pharmacology (J Pharm Pharmacol) Vol. 41 Issue 7 Pg. 488-9 (Jul 1989) ISSN: 0022-3573 [Print] England
• PMID: 2570857 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• 6-methylene-4-pregnene-3,20-dione
• Progesterone

Topics

• Adenoma (drug therapy, physiopathology)
• Animals
• Disease Models, Animal
• Humans
• Male
• Mice
• Mice, Nude
• Neoplasm Transplantation
• Organ Size (drug effects)
• Progesterone (analogs & derivatives, therapeutic use)
• Prostate (drug effects)
• Prostatic Neoplasms (drug therapy, physiopathology)
• Seminal Vesicles (drug effects)